Usefulness of Ivermectin in COVID-19 Illness
Amit N. Patel MD, MS1,2; Sapan S. Desai MD PhD MBA3
David W. Grainger PhD1, Mandeep R. Mehra,MD, MSc4
1Department of Bioengineering, University of Utah, Salt Lake City, UT;
2HCA Research Institute, Florida;
3Surgisphere Corporation, Chicago, Illinois;
4Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA;
Design: An international, multicenter, observational propensity-score matched case-controlled
study using prospectively collected data on patients diagnosed with COVID-19 between January
1, 2020 and March 31, 2020.
Participants: Hospitalized patients diagnosed with COVID-19 determined by presence of a
positive laboratory finding confirming SARS-CoV-2 infection.
Exposure: Ivermectin (150mcg/Kg) administered once compared with COVID-19 patients
receiving medical therapy without ivermectin.
"Findings: This observational propensity-matched case-controlled study in 1,408 patients (704
that received ivermectin and 704 that did not) demonstrated an association of ivermectin use
with lower in-hospital mortality 1.4% versus 8.5% (Ivermectin versus no ivermectin; HR 0.20 CI
95% 0.11-0.37, p<0.0001)."
https://www.isglobal.org/documents/10179/6022921/Patel+et+al.+2020+version+2.pdf/adf390e0-7099-4c70-91d0-e0f7a0b69e14